AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11815895
Drug: Oral antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antioxidant micronutrient mixture (beta-carotene 18 mg/day, vitamin C 750 mg/day, vitamin E 600 mg/day)
Trial: 10070054
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose concentration at 4 mmol/l
Trial: 10070054
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose concentration at 9 mmol/l
Trial: 1849133
Drug: OKY-046 (thromboxane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKY-046 (thromboxane A2 synthetase inhibitor)
Trial: 31416357
Drug: Oral anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulation plus platelet inhibition (OAC+PI)
Trial: 26917112
Drug: ATV/r 300/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATV/r 300/100 mg once daily
Trial: 21842159
Drug: Ayahuasca (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ayahuasca (0.75 mg DMT/kg bodyweight)
Trial: 19398067
Drug: 3g of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3g of oral Myelophil per day
Trial: 17124249
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment delivered in hospital (ATH)
Trial: 12037070
Drug: Indinavir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir treatment arm
Trial: 12037070
Drug: Dual-nucleoside treatment
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-nucleoside treatment arm
Trial: 12037070
Drug: Indinavir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir treatment arm (plasma HIV-1 RNA <500 copies/ml)
Trial: 12037070
Drug: Indinavir treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir treatment arm (plasma HIV-1 RNA >or=500 copies/ml)
Trial: 12037070
Drug: Samples with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Samples with plasma RNA levels <50 copies/ml
Trial: 12016904
Drug: roxithromycin dispersible
RxNorm normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roxithromycin dispersible tablet (formulation A)
Trial: 12016904
Drug: conventional tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: conventional tablet (formulation B)
Trial: 2173646
Drug: No drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drug therapy between shocks
Trial: 210476
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg chlorpromazine
Trial: 3330184
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg chlorpromazine
Trial: 11421842
Drug: Tramadol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 1.5 mg kg(‐1)
Trial: 16525746
Drug: Oral sodium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium phosphate (Fleet)
Trial: 16525746
Drug: Picoprep (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picoprep (sodium picosulfate-based preparation)
Trial: 12525827
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa; NovoSeven®) administered as a 90- to 110-μg/kg bolus dose every second hour.
Trial: 12525827
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa; NovoSeven®) administered for major surgery and life-threatening bleeding.
Trial: 12525827
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa; NovoSeven®) with longer intervals between doses after the first 24 hours.
Trial: 12525827
Drug: Recombinant activated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant activated factor VII (rFVIIa; NovoSeven®) at higher doses in in vitro experiments.
Trial: 10770171
Drug: Physiological study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological study (hydrocortisone infusion for 48 h in a pulsatile and diurnal pattern)
Trial: 10770171
Drug: Constant study
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant study (same total dose of hydrocortisone as physiological study, but with pulses of equal magnitude spaced evenly)
Trial: 10770171
Drug: Reversed study
RxNorm normalized name: Revertased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reversed study (same total dose of hydrocortisone, but with diurnal pattern shifted 12 h)
Trial: 10770171
Drug: Baseline study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline study (saline infusion for 48 h)
Trial: 8851456
Drug: 10-mg CR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg CR oxycodone tablet every 12 hours for 4 days
Trial: 8851456
Drug: 5 mL
RxNorm normalized name: WATER,INHL 5 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mL of 1-mg/1 mL IR oxycodone solution every 6 hours for 4 days
Trial: 6726654
Drug: Imipramine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine with cimetidine (300 mg every 6 hr)
Trial: 22009369
Drug: Intravenous bolus
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous bolus of lipopolysaccharide (LPS, 4 ng/kg)
Trial: 16767525
Drug: 250 microg
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 microg daily nasal hPTH(1-34) spray for 3 months
Trial: 16767525
Drug: 500 microg
RxNorm normalized name: Etizolam 500 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 microg daily nasal hPTH(1-34) spray for 3 months
Trial: 16767525
Drug: 1,000 microg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 microg daily nasal hPTH(1-34) spray for 3 months
Trial: 16767525
Drug: Daily supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplements of 300 mg calcium and 200 IU vitamin D(3)
Trial: 14517200
Drug: Sirolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (10 mg oral dose) alone
Trial: 14517200
Drug: Sirolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (10 mg oral dose) administered 4 hours after CsA (300 mg oral dose)
Trial: 14517200
Drug: Cyclosporine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (300 mg oral dose) alone
Trial: 14517200
Drug: Sirolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sirolimus (10 mg oral dose)
Trial: 15644588
Drug: Pravastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (20 mg/day)
Trial: 9200296
Drug: Observation (conservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (conservative treatment)
Trial: 7827590
Drug: Indole-3-carbinol (I3C)
DrugBank: Indole-3-carbinol (DB12881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indole-3-carbinol (I3C) 400 mg/day for 3 months
Trial: 7827590
Drug: Alpha-cellulose 20
RxNorm normalized name: ALPHA CELLULOSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-cellulose 20 g/day for 3 months
Trial: 3402101
Drug: Water instillation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water instillation (1 drop 0.05 ml, 2 drops 0.1 ml, or no water)
Trial: 26232311
Drug: 2-L polyethylene
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-L polyethylene glycol-citrate-simethicone plus 2-day bisacodyl
Trial: 26232311
Drug: 4-L polyethylene
RxNorm normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-L polyethylene glycol
Trial: 24827127
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate 2.0 mg/m² on day 1 with erlotinib 150 mg on days 2-16 (21-day regimen)
Trial: 24827127
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate 1.4 mg/m² on days 1 and 8 with erlotinib 150 mg on days 15-28 (28-day regimen)
Trial: 20102890
Drug: Quinapril 40
RxNorm normalized name: quinapril 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril 40 mg/day orally (n = 43)
Trial: 18600119
Drug: Effective nursing
RxNorm normalized name: PAD,NURSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effective nursing interventions conducted daily for 45 to 60 minutes after the 7th to 10th day of chemotherapy
Trial: 12177105
Drug: Motexafin gadolinium
RxNorm normalized name: Motexafin gadolinium
DrugBank: Motexafin gadolinium (DB05428)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motexafin gadolinium (5.0 mg/kg/d for 10 days) administered before each radiation treatment
Trial: 1472933
Drug: Busulfan (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Busulfan (conventional treatment)
Trial: 1472933
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (hydrea or busulfan)
Trial: 29404931
Drug: Trial formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trial formulation
Trial: 24779438
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment and care (control group)
Trial: 15640477
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1000 mg calcium carbonate/d)
Trial: 12047486
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of ayahuasca (0.6 mg DMT kg(‐1) body weight)
Trial: 12047486
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of ayahuasca (0.85 mg DMT kg(‐1) body weight)
Trial: 8479131
Drug: Ketoacid supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoacid supplement (KA)
Trial: 8479131
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid supplement (AA)
Trial: 15173777
Drug: Dipyridamole administration
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole administration
Trial: 31597315
Drug: Quercetin (CM+Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin (CM+Q group), administered orally for 3-5 days before catheterization.
Trial: 25362220
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group - received 1000 mL of normal saline before CAA
Trial: 22395527
Drug: Lurasidone (40-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (40-120 mg)
Trial: 19900349
Drug: Risperidone (2-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (2-6 mg)
Trial: 18625622
Drug: 8 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/kg tocilizumab
Trial: 18625622
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg tocilizumab
Trial: 11279947
Drug: Fluoxetine 20
RxNorm normalized name: fluoxetine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg per day
Trial: 7739706
Drug: Fluoxetine 60
RxNorm normalized name: fluoxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 60 mg per day
Trial: 1962901
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMW heparin) administered subcutaneously once daily according to body weight classes (55 to 65 Factor‐Xa inhibitory U/kg) for 14 days
Trial: 116298
Drug: Naloxone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (20 mg IV)
Trial: 21200337
Drug: PDA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDA with daily tailored feedback message (PDA + FB)
Trial: 17905915
Drug: Syntactic-semantic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syntactic-semantic therapy
Trial: 17905915
Drug: Semantic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Semantic therapy
Trial: 26673292
Drug: Gene engineering
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene engineering technologies of angiogenesis stimulation as an independent method of treatment in comprehensive conservative therapy (80 patients)
Trial: 26673292
Drug: Gene engineering
RxNorm normalized name: acellular tissue engineered vessel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gene engineering technologies of angiogenesis stimulation as comprehensive treatment in combination with revascularizing operations (80 patients)
Trial: 12808401
Drug: Nonpreserved lubricants,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonpreserved lubricants, topical steroidal and nonsteroidal anti-inflammatory agents, punctal plugs for aqueous-deficient dry eye, mechanical removal of filaments, hypertonic saline, mucolytic agents, and bandage contact lenses.
Trial: 12808401
Drug: Alternate medications
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate medications or additional measures to manage the tear film and ocular surface.
Trial: 1610631
Drug: Demand top-ups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Demand top-ups of 0.25% plain bupivacaine 10 ml
Trial: 1610631
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.125% plain bupivacaine 10 ml h‐1
Trial: 1610631
Drug: Patient-controlled extradural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-controlled extradural analgesia (PCEA) delivering 3-ml boluses of 0.25% bupivacaine
Trial: 3968329
Drug: Bitolterol aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bitolterol aerosol (three sprays, 1.11 mg)
Trial: 3968329
Drug: Albuterol aerosol
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol aerosol (two sprays, 180 mcg)
Trial: 27444660
Drug: ONO‐6950 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ONO‐6950 (200 mg)
Trial: 22160854
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg daily plus TMZ 150 mg/m(2)/day for 5 days every 28 days (NEIAEDs)
Trial: 22160854
Drug: Everolimus (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (various doses) plus TMZ (150 mg/m(2)/day) (EIAEDs)
Trial: 21055801
Drug: 1 μg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 μg/day paricalcitol
Trial: 21055801
Drug: 2 μg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 μg/day paricalcitol
Trial: 10557953
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low doses of estrogen combined with vitamin D and calcium
Trial: 10557953
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy with very low doses of estrogen
Trial: 8556189
Drug: Dofetilide (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dofetilide (0.1 to 8.0 ng/mL)
Trial: 1683403
Drug: Cabergoline 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 1.0 mg
Trial: 1683403
Drug: Cabergoline 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 0.75 mg
Trial: 1683403
Drug: Cabergoline 0.5
RxNorm normalized name: cabergoline 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline 0.5 mg
Trial: 17316466
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of hydrocortisone
Trial: 11455143
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (topical corticosteroid + barrier cream)
Trial: 2590625
Drug: Topical corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical corticosteroid
Trial: 11455143
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (fourth patch)
Trial: 2513047
Drug: Calcium channel
RxNorm normalized name: Calcium channel blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium channel blockers (active treatment)
Trial: 785427
Drug: Adsorbed surface-antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adsorbed surface-antigen influenza vaccine
Trial: 24021959
Drug: Selegiline transdermal
RxNorm normalized name: Selegiline Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline transdermal system (STS) 6 mg/24h
Trial: 21240530
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (undercutting laminectomy augmented with transpedicular-instrumented fusion)
Trial: 11524464
Drug: Mylan extended-release
RxNorm normalized name: hylan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mylan extended-release phenytoin sodium capsules with food
Trial: 31446180
Drug: Genotype analysis
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype analysis for NUDT15, FTO, and TPMT variants; patients heterozygous for any variant received 50 mg azathioprine equivalents, homozygous patients received alternative drugs; those without variants and non-genotyping group received 50 mg azathioprine equivalents with dose escalation.
Trial: 31446180
Drug: Non-genotyping group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-genotyping group (no genotype analysis); received 50 mg azathioprine equivalents followed by dose escalation.
Trial: 31446180
Drug: Maximum dose
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum dose of thiopurines
Trial: 18638649
Drug: Therapy as
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy as usual
Trial: 22094353
Drug: Atorvastatin (AT,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (AT, n=17)
Trial: 24007717
Drug: Hormone Therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone Therapy (HT, n=34)
Trial: 24007717
Drug: Hormone Therapy
RxNorm normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormone Therapy plus Atorvastatin (HT+AT, n=36)
Trial: 10930822
Drug: Atorvastatin (AT)
RxNorm normalized name: AT 10
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin (AT)
Trial: 3536262
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy plus salmon calcitonin 100 MRC units daily for 3 weeks (Group II)
Trial: 3536262
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy alone (Group I)
Trial: 1454457
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg d-amphetamine
Trial: 24721024
Drug: Procedural sedation
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procedural sedation analgesia (SA) with ketamine 1 to 2 mg/kg intravenously
Trial: 11465654
Drug: Lisinopril and
RxNorm normalized name: lisinopril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril and Losartan
Trial: 9629934
Drug: Less intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less intensive treatment programs
Trial: 2896556
Drug: Atenolol (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (beta 1-selective blocker)
Trial: 3993547
Drug: Propranolol (nonselective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (nonselective beta-blocker)
Trial: 30289485
Drug: Dapivirine vaginal
RxNorm normalized name: dapivirine
DrugBank: Dapivirine (DB08639)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapivirine vaginal ring (25 mg DPV)
Trial: 25615629
Drug: Prefix 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prefix 750 (750 μg/cm(3) granules)
Trial: 25615629
Drug: Prefix 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prefix 150 (150 μg/cm(3) granules)
Trial: 24199982
Drug: Conventional periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional periodontal treatment (CPT) and homeopathic medicine (HM)
Trial: 24199982
Drug: Conventional periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional periodontal treatment (CPT)
Trial: 21606877
Drug: Cooling collar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooling collar from the start (CC)
Trial: 21606877
Drug: Cooling collar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cooling collar replaced at 30‐min intervals (CC(replaced))